{"classes":[{"categories":[{"measurements":[{"comment":"The geometric coefficient of variation was statistically non-estimable for this dataset at Week 1 (Study Day 1).","groupId":"OG000","spread":"NA","value":"42.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"}],"units":"Participants"}],"title":"Week 1 (Study Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.54","value":"69.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"title":"Week 9 (Study Day 57)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.68","value":"56.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"title":"Week 17 (Study Day 113)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"}],"units":"Participants"}],"description":"Ctrough of MEK162 is defined as the predose plasma concentration of MEK162. Ctrough of MEK162 was observed directly from data.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received an oral dose of 45 milligram (mg) of MEK162 tablets (3 tablets of 15 mg) twice daily for each 28-day treatment cycle until disease progression, withdrawal of consent, initiation of subsequent anticancer therapy, lost to follow-up or death, whichever occurred first. Participants were followed up to 30 days after last dose of study intervention.","id":"OG000","title":"MEK162"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The pharmacokinetics (PK) set consisted of all participants who received at least 1 dose of MEK162 and had at least 1 PK blood collection with associated bioanalytical results.","reportingStatus":"POSTED","timeFrame":"Predose on Study Days 1, 57, and 113.","title":"Predose Plasma Concentration (Ctrough) of MEK162","type":"SECONDARY","unitOfMeasure":"nanograms per milliliter (ng/mL)"}